Study guide
6.2 Stability, Shelf-Life, and Manufacturing
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
6.2 Stability, Shelf-Life, and Manufacturing
Key Takeaways Explain This Topic AI
Zero-order kinetics have a constant rate independent of concentration; first-order rate is proportional to concentration and yields a constant half-life t1/2 = 0.693/k.
Shelf-life t90 is the time for a product to retain 90% of labeled potency; for first-order decay t90 = 0.105/k.
The Arrhenius equation, k = A·exp(−Ea/RT), lets formulators extrapolate shelf-life from accelerated stability data at elevated temperatures.
Chemical degradation proceeds via hydrolysis, oxidation, and photolysis; stabilization uses buffers, antioxidants, chelating agents, amber containers, and nitrogen flushing.
cGMP governs manufacturing: validated wet and dry granulation, compression, coating, and quality control tests (content uniformity, dissolution, hardness, friability) assure identity, strength, quality, purity, and potency.
Last updated: July 2026
Reaction Kinetics in Drug Stability
Drug degradation is modeled with the same rate laws used in general chemistry. Knowing the order tells the formulator how concentration affects shelf-life and how to extrapolate accelerated data.
Zero-order : rate is constant, independent of drug concentration. dC/dt = −k0. Example: suspension suspensions where the surface area of excess solid maintains a saturated solution. Half-life depends on initial concentration: t1/2 = C0 / (2k0).
First-order : rate proportional to concentration. dC/dt = −k1·C. Most drug degradations follow first-order kinetics. Half-life t1/2 = 0.693/k1 is independent of C0.
Second-order : rate proportional to product of two concentrations (or squared). dC/dt = −k2·C². Common when two drug molecules react together.
Pseudo-order : a reactant is in vast excess so its concentration is effectively constant, and a higher-order reaction collapses to a lower apparent order (e.g., hydrolysis in water is pseudo-first-order because water concentration is ~55.5 M).
- Order Rate law Integrated t1/2 Real example
- 0 −k0 C = C0 − k0·t C0/(2k0) Aspirin suspension hydrolysis at fixed pH
- 1 −k1·C ln C = ln C0 − k1·t 0.693/k1 Most solution degradation, ampicillin in solution
- 2 −k2·C² 1/C = 1/C0 + k2·t 1/(k2·C0) Dimerization of some proteins
- Shelf-Life Determination and Accelerated Stability
Pharmaceutical shelf-life (expiration date) is the time the product remains within specification when stored under labeled conditions. The conventional potency cutoff is 90% of labeled claim , defining t90 . For first-order decay, t90 = ln(0.90)/(−k) ≈ 0.105/k .
Accelerated stability testing uses elevated temperature to provoke degradation quickly, then extrapolates to refrigerator or room-temperature conditions using the Arrhenius equation :
k = A · exp(−Ea / (R · T))
where k is the rate constant, A the pre-exponential factor, Ea the activation energy, R the gas constant (8.314 J·mol⁻¹·K⁻¹), and T the absolute temperature. Plotting ln k versus 1/T (Kelvin) yields a straight line whose slope equals −Ea/R. Once Ea is known, the formulator calculates k at 25 °C and the corresponding t90.
ICH guidance recommends: long-term (25 °C/60% RH, 12 months), intermediate (30 °C/65% RH, 6 months), and accelerated (40 °C/75% RH, 6 months) conditions. A product that remains within specification at accelerated conditions for six months generally supports a tentative 24-month shelf-life at room temperature, confirmed by long-term data.
Physical and Chemical Stability
Physical instability changes appearance or performance without breaking covalent bonds: polymorphic conversion (anhydrous ↔ hydrate), hygroscopic uptake of water, crystal growth in suspensions, phase separation in emulsions, caking, color change, odor development. Polymorphic transitions can collapse solubility — the metastable form of ritonavir (Form II) precipitated from capsules in 1998, forcing a market withdrawal.
Chemical instability breaks the drug molecule:
Hydrolysis — esters, amides, lactams, lactones cleave in water; catalyzed by acid, base, or specific pH. Aspirin hydrolyzes to salicylic acid and acetic acid; penicillins and cephalosporins hydrolyze at the beta-lactam ring.
Oxidation — electron loss, often initiated by light, trace metals, or oxygen. Examples: vitamin A, ascorbic acid, epinephrine, morphine (turns brown), nitroprusside. Stabilize with antioxidants (BHA, BHT, ascorbic acid, sodium metabisulfite), chelating agents (EDTA binds Fe²⁺/Cu²⁺ that catalyze Fenton chemistry), nitrogen flushing , and amber containers that block UV.
Photolysis — UV-visible absorption excites the molecule; nifedipine, riboflavin, nitrofurazone are notoriously photolabile. Use amber or opaque packaging and store protected from light.
Drug Product Manufacturing under cGMP
Current Good Manufacturing Practice (cGMP) is the FDA regulatory framework (21 CFR 210/211) that assures identity, strength, quality, purity, and potency. Validation, batch records, deviation management, change control, and stability commitment are continuous obligations, not one-time checks.
Tablet manufacturing routes:
Wet granulation — binder solution aggregates powder into granules of uniform size; dries, mills, blends with lubricant, compresses. Ideal for low-dose drugs (improves content uniformity) and poor-flow powders.
Dry granulation — roller compaction or slugging forms granules without water; suited for water-sensitive drugs.
Direct compression — compresses pre-blended API and excipients; fewest steps, but requires good-flow excipients (microcrystalline cellulose, spray-dried lactose).
Coating — sugar, film, or enteric polymer applied in pan or fluidized-bed coaters. Film coats protect the drug, mask taste, and improve appearance; enteric coats resist gastric acid and dissolve in the intestine (pH ~6.8).
Quality Control Tests
Content uniformity — assures each unit contains 85-115% of label claim with low variability (USP <905>).
Dissolution testing — USP Apparatus 1/2 with Q-point specifications (e.g., Q=80% in 45 min).
Hardness (crushing strength) — affects disintegration and handling; typically 4-10 kg for tablets.
Friability — weight loss after drum rotation (USP <1216>); must be <1%.
Disintegration — bounded time limits in specified media (USP <701>).
Assay and impurities — HPLC/UPLC quantitation of API and degradation products against ICH Q3B thresholds.
Formulation-Biological Interactions
Excipients and food can change absorption. Food effects : a high-fat meal can slow gastric emptying and alter dissolution for poorly soluble drugs, sometimes doubling exposure (grapefruit juice inhibits intestinal CYP3A4, raising statin levels). Excipient interactions : calcium and magnesium antacids chelate fluoroquinolones and tetracyclines, sharply reducing bioavailability. Lactose in large doses can raise blood glucose; sorbitol can cause diarrhea. Such interactions explain why bioequivalence studies use fasting and fed arms.